A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
Vincent A de WegerSanjay GoelRoger von MoosJan H M SchellensNicholas MachEugene TanSuraj AnandJeffrey W ScottUlrik LassenPublished in: Cancer chemotherapy and pharmacology (2017)
Fluvoxamine co-administration resulted in a 80% increase in C max and a 188% increase in AUC0-72h of dovitinib. Given the increase in exposure to dovitinib observed, patients are at risk of dovitinib related toxicity. Dovitinib should, therefore, not be co-administered with moderate and strong CYP1A2 inhibitors, without dose reduction.